Case Name: Sandoz, Inc. v. Novo Nordisk, Inc. et al.
Docket Number: 2:11-cv-13594-AC-MAR
Date Filed: 08/17/2011
Judge: Hon. Avern Cohn
Sandoz, Inc. (“Plaintiff”) filed suit against Novo Nordisk, Inc. and Novo Nordisk A/S (“Defendants”) for declaratory judgment of non-infringement, invalidity, and unenforceability regarding U.S. Patent No. 6,677,358 (“the ‘358 patent”), entitled “NIDDM regimen.” Defendant’s produce a name-brand drug, Prandin under protection of the ‘358 patent and Plaintiff’s wish to market a generic version of Prandin. The ‘358 patent generally relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering, in connection with the meals, a short-acting oral hypoglycaemic agent.
Ultimately, an agreement was reached between the parties after the resolution of another case involving Defendants. As a result, on October 29, 2013, the court entered a stipulated order of dismissal.